Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
Fiche du document
- doi: 10.1002/jbmr.4764
- issn: 0884-0431
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/jbmr.4764
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36588166
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1523-4681
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_210A7E8BE4274
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Womyn Wimmin Woman Womon Human females Women's workCiter ce document
F. Cosman et al., « Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend. », Serveur académique Lausannois, ID : 10.1002/jbmr.4764
Métriques
Partage / Export
Résumé
Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T-scores > -2.5. Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk independent of BMD. We evaluated whether abaloparatide improves TBS and whether TBS trends were associated with vertebral fracture risk reduction. Women with osteoporosis randomized to abaloparatide or placebo for 18 months (ACTIVE), followed by alendronate for 24 months (ACTIVExtend), with evaluable TBS, were included in this post hoc analysis (N = 911). TBS was calculated from spine BMD scans using an algorithm adjusted for tissue thickness (TBS th ) at baseline, 6, 18, and 43 months. Mean increments in TBS th from baseline within and between treatment groups, proportion of women with TBS th increments above least significant change (LSC) and proportion with degraded TBS th (